These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 17460562

  • 21. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
    Hess G, Flohr T, Huber C, Kolbe K, Derigs HG, Fischer T.
    Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
    [Abstract] [Full Text] [Related]

  • 22. Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD).
    Giraldi E, Provenzi M, Fiocchi R, Colledan M, Cornelli P, Torre G, Rambaldi A, Conter V.
    Pediatr Blood Cancer; 2011 Aug; 57(2):324-8. PubMed ID: 21294246
    [Abstract] [Full Text] [Related]

  • 23. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
    Domingo-Domènech E, González-Barca E, Estany C, Sureda A, Besalduch J, Fernández de Sevilla A.
    Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
    [Abstract] [Full Text] [Related]

  • 24. Long-term survival after post-transplant lymphoproliferative disease in children.
    Nathanson S, Debray D, Delarue A, Deschênes G.
    Pediatr Nephrol; 2002 Aug; 17(8):668-72. PubMed ID: 12185479
    [Abstract] [Full Text] [Related]

  • 25. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, Troch M, Puspok A, Zielinski CC, Chott A.
    Oncology; 2006 Aug; 70(6):411-7. PubMed ID: 17220639
    [Abstract] [Full Text] [Related]

  • 26. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V, Molica S, Capalbo S, Pogliani E, Battista C, Broccia G, Montillo M, Cuneo A, Leoni P, Specchia G, Castoldi G.
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [Abstract] [Full Text] [Related]

  • 27. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V.
    Ann Oncol; 2000 Nov; 11 Suppl 1():113-6. PubMed ID: 10707791
    [Abstract] [Full Text] [Related]

  • 28. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ, Lam MS, Rosenberg A.
    Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
    [Abstract] [Full Text] [Related]

  • 29. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dörken B, Trappe R.
    Ann Hematol; 2007 Aug; 86(8):599-607. PubMed ID: 17522862
    [Abstract] [Full Text] [Related]

  • 30. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
    Patel H, Vogl DT, Aqui N, Shaked A, Olthoff K, Markmann J, Reddy R, Stadtmauer EA, Schuster S, Tsai DE.
    Leuk Lymphoma; 2007 May; 48(5):885-91. PubMed ID: 17487731
    [Abstract] [Full Text] [Related]

  • 31. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
    Mamzer-Bruneel MF, Lomé C, Morelon E, Levy V, Bourquelot P, Jacobs F, Gessain A, Mac Intyre E, Brousse N, Kreis H, Hermine O.
    J Clin Oncol; 2000 Nov 01; 18(21):3622-32. PubMed ID: 11054435
    [Abstract] [Full Text] [Related]

  • 32. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M, Lagoo AS, Szabolcs P, Chiu J, Comito M, Buckley PJ.
    Am J Surg Pathol; 2006 Mar 01; 30(3):328-36. PubMed ID: 16538052
    [Abstract] [Full Text] [Related]

  • 33. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun 01; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 34. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series.
    Avolio AW, Agnes S, Barbarino R, Magalini SC, Frongillo F, Pagano L, Larocca LM, Pompili M, Caira M, Sollazzi L, Castagneto M.
    Transplant Proc; 2007 Jun 01; 39(6):1956-60. PubMed ID: 17692665
    [Abstract] [Full Text] [Related]

  • 35. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
    Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, Bosi A.
    Hematol Oncol; 2007 Dec 01; 25(4):198-203. PubMed ID: 17654614
    [Abstract] [Full Text] [Related]

  • 36. Monotherapy rapamycin in renal transplant recipients with lymphoma successfully treated with rituximab.
    Alexandru S, Gonzalez E, Grande C, Hernandez A, Morales E, Praga M, Andres A, Morales JM.
    Transplant Proc; 2009 Dec 01; 41(6):2435-7. PubMed ID: 19715944
    [Abstract] [Full Text] [Related]

  • 37. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
    Jain M, Badwal S, Pandey R, Srivastava A, Sharma RK, Gupta RK.
    Clin Transplant; 2005 Oct 01; 19(5):668-73. PubMed ID: 16146560
    [Abstract] [Full Text] [Related]

  • 38. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA, Hamilton-Dutoit S, Bendtzen K.
    Transplantation; 2003 Jul 15; 76(1):153-8. PubMed ID: 12865802
    [Abstract] [Full Text] [Related]

  • 39. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
    Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppä S.
    Clin Cancer Res; 2007 Oct 01; 13(19):5784-9. PubMed ID: 17908969
    [Abstract] [Full Text] [Related]

  • 40. Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
    Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU.
    Transplantation; 2012 Mar 15; 93(5):543-50. PubMed ID: 22234349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.